Therefore, establishing [18F]PI-2620 as a 4R tau biomarker holds the potential to transform molecularly informed PSP diagnosis, to gain mechanistic insights into PSP pathophysiology, to benchmark other candidate 4R tau biomarkers and to track disease progression in clinical trials. Here, MAPT is linked to supranuclear palsy, progressive, 1.